内蒙古建中律师事务所 关于金宇生物技术股份有限公司 2024 年年度股东大会的法律意见书 2025 内建中券意字第 18 号 致：金宇生物技术股份有限公司 内蒙古建中律师事务所（以下称"本所"）受金宇生物技术股份有限公司（以 下称"贵公司"或"公司"）的委托，指派本所执业律师郭瑞鹏、王磊（以下称 "本所经办律师"）出席了贵公司 2024 年年度股东大会（以下称"本次股东大 会"），并根据《中华人民共和国证券法》（以下称"《证券法》"）、《中华 人民共和国公司法》（以下称"《公司法》"）和中国证监会《上市公司股东会 规则》（以下称"《股东会规则》"）等法律、法规和规范性文件以及《金宇生 物技术股份有限公司章程》（以下称"《章程》"）的规定，就本次股东大会的 召集、召开程序、出席会议人员资格以及表决程序和表决结果的合法有效性出具 本法律意见书。 为出具本法律意见书，本所经办律师已对本次股东大会所涉及的有关事项及 文件资料进行了必要的核查和验证，且贵公司已对前述资料的真实性和准确性向 本所作了保证。 本法律意见书仅供贵公司为本次股东大会的适当目的使用，不得被任何人用 于其他任何目的。 本所同意贵公司将本法律意见书作 ...

证券代码：600201 证券简称：生物股份 公告编号：临 2025-028 金宇生物技术股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 2、公司在任监事3人，出席3人； 3、董事会秘书彭敏、公司副总裁李荣出席了本次股东大会。 二、 议案审议情况 (一)股东大会召开的时间：2025 年 5 月 28 日 (二)股东大会召开的地点：内蒙古自治区呼和浩特市经济技术开发区沙尔沁工业 园区金宇大街 1 号公司会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 284 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 142,679,384 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 12.7350 | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况 ...

证券代码：600201 证券简称：生物股份 公告编号：临 2025-029 金宇生物技术股份有限公司 第十二届董事会第一次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 金宇生物技术股份有限公司（以下简称"公司"）第十二届董事会第一次会议 于 2025 年 5 月 28 日下午 16：30 在公司会议室以现场表决方式召开，应出席董事 8 人，实际出席董事 8 人。公司于 2025 年 5 月 28 日召开的 2024 年年度股东大会 审议通过了董事会换届选举事项,为确保本届董事会尽快开展工作，经全体董事一 致同意，决定于同日召开第十二届董事会第一次会议。本次会议通知豁免时间要 求，并以电话、口头等方式送达。公司高级管理人员列席了会议，会议的召集、 召开程序符合《公司法》及《公司章程》的规定。参会董事共同推举张翀宇先生 主持本次会议，会议审议通过了如下议案： 一、审议并通过《关于选举公司董事长、副董事长的议案》 公司第十二届董事会成员已经公司 2024 年年度股东大会审议通过并确定,根 据《公司法》和《公司章程》等 ...

Core Viewpoint - The China Securities Index for Agriculture, Animal Husbandry, and Fishery (CSI Agricultural Index) shows a slight increase of 0.32% on May 27, with a trading volume of 8.955 billion yuan, reflecting a mixed performance in the agricultural sector over different time frames [1]. Group 1: Index Performance - The CSI Agricultural Index has decreased by 0.29% over the past month, increased by 5.17% over the past three months, and has risen by 2.23% year-to-date [1]. - The index is structured to reflect the overall performance of various industry companies, categorized into 11 primary industries, 35 secondary industries, over 90 tertiary industries, and more than 200 quaternary industries [1]. Group 2: Index Holdings - The top ten holdings in the CSI Agricultural Index are: Muyuan Foods (14.86%), Wens Foodstuff Group (14.49%), Haida Group (10.64%), New Hope Liuhe (4.54%), Meihua Holdings (4.47%), Dabeinong Technology Group (2.95%), Longping High-Tech (2.2%), Beidahuang Group (2.16%), Shennong Development (1.99%), and Biological Products (1.71%) [1]. - The market share of the CSI Agricultural Index holdings is 73.03% from the Shenzhen Stock Exchange and 26.97% from the Shanghai Stock Exchange [1]. Group 3: Sample Adjustments - The index samples are adjusted biannually, with adjustments occurring on the next trading day after the second Friday of June and December [2]. - Weight factors are generally fixed until the next scheduled adjustment, with temporary adjustments made in response to special events affecting sample companies [2]. Group 4: Related Funds - Public funds tracking the agricultural sector include Huabao CSI Agricultural Index Fund A and Huabao CSI Agricultural Index Fund C [3].

Group 1 - The China Livestock Breeding Index (930707) increased by 0.05% as of May 27, 2025, with notable gains from companies such as Ruip Bio (300119) up 1.68% and Yike Food (301116) up 1.44% [1] - The Livestock ETF (516760) rose by 0.16%, with a latest price of 0.63 yuan, and has accumulated a 0.64% increase over the past two weeks [1] - The Livestock ETF has shown a net value increase of 3.27% over the past six months, with a maximum single-month return of 17.22% since its inception [1] Group 2 - Sichuan Province has drafted ten measures to promote high-quality development in the livestock industry, focusing on strengthening leading enterprises and supporting their participation in large-scale projects [2] - The measures aim to enhance the capabilities of leading livestock enterprises to drive the development of farms and households [2] Group 3 - Short-term pig prices are expected to remain stable, with a balanced supply-demand situation anticipated in the second half of the year, leading to a more optimistic outlook for pig price expectations and profitability of pig enterprises [3] - Current pig prices allow for slight profitability for breeding enterprises, but the industry faces challenges in capacity reduction, with cost competition becoming a key focus [3] Group 4 - As of May 26, 2025, the Livestock ETF has experienced a maximum drawdown of 5.00% this year, with a management fee of 0.50% and a custody fee of 0.10% [5] - The Livestock ETF tracks the China Livestock Breeding Index, which has a current price-to-earnings ratio (PE-TTM) of 12.33, indicating a historical low valuation [5] - The top ten weighted stocks in the China Livestock Breeding Index account for 69.38% of the index, with companies like Haida Group (002311) and Muyuan Foods (002714) being the largest contributors [5]

Summary of Key Points Core Viewpoint - The announcement details the provision of a guarantee by Qingdao Weilan Biological Co., Ltd. for its subsidiary, Qingdao Weilan Longchu Biotechnology Co., Ltd., to support its credit activities with a total guarantee amount of RMB 178,950.00 million for the fiscal year 2025 [1][2]. Group 1: Guarantee Overview - The guaranteed entity is Qingdao Weilan Longchu Biotechnology Co., Ltd. [1] - The total guarantee amount provided is RMB 178,950.00 million, with the current balance being reported [2]. - The guarantee does not have any counter-guarantee [1]. - There are no overdue guarantees reported [1]. Group 2: Approval Process - The guarantee was approved by the company's board meeting on April 25, 2025, and subsequently by the annual shareholders' meeting on May 16, 2025 [2]. - The details of the guarantee were disclosed in announcements on April 26, 2025, and May 17, 2025 [2]. Group 3: Financial Status of the Guaranteed Entity - Qingdao Weilan Longchu Biotechnology Co., Ltd. was established on August 11, 2011, with a registered capital of RMB 33.50 million [3]. - The total assets of the company are reported at RMB 79,627.70 million, with total liabilities at RMB 41,997.90 million, resulting in net assets of RMB 37,629.80 million [4]. - The company's revenue for the audited period is RMB 83,549.20 million, with a net profit of RMB 4,286.00 million [4]. Group 4: External Guarantee Status - The total amount of external guarantees provided by the company and its subsidiaries is RMB 91,420.00 million, which constitutes 52.61% of the net assets attributable to shareholders as of December 31, 2024 [4][5]. - There are no overdue guarantees as of the announcement date [5].

证券代码：603739 证券简称：蔚蓝生物 公告编号：2025-023 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 每股分配比例 A 股每股现金红利0.10元 ? 相关日期 | 股份类别 | 股权登记日 | | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | --- | | Ａ股 | 2025/5/29 | － | 2025/5/30 | 2025/5/30 | | ? 差异化分红送转： 否 一、 通过分配方案的股东会届次和日期 本次利润分配方案经公司2025 年 5 月 16 日的2024年年度股东会审议通过。 二、 分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分 公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 本次利润分配以方案实施前的公司总股本253,028,866股为基数，每股派发现金红利0.10 元（含税） ，共计派发现金红利25,302,886.60元。 三、 相关 ...

证券代码：600538 证券简称：国发股份 公告编号：临2025-025 特此公告。 北海国发川山生物股份有限公司 北海国发川山生物股份有限公司（以下简称"公司"）近日收到独立董事曾艳琳女士的书面辞职报告。曾 艳琳女士因个人原因向公司董事会提出辞去公司第十一届董事会独立董事、董事会提名委员会主任委员 和董事会战略委员会委员的职务，辞职后不再公司担任任何职务。截至本公告披露日，曾艳琳女士未直 接或间接持有公司股份，亦不存在应当履行而未履行的承诺事项。 根据《中华人民共和国公司法》《上市公司独立董事管理办法》《上海证券交易所股票上市规则》《上 海证券交易所上市公司自律监管指引第1号一一规范运作》以及《公司章程》等相关规定，由于曾艳琳 女士辞职将导致公司独立董事人数少于董事会人数的三分之一，且董事会提名委员会及战略委员会中独 立董事所占比例不符合《上市公司独立董事管理办法》以及公司章程的规定，其辞职报告将在公司股东 大会选举产生新的独立董事后生效。在此之前，曾艳琳女士将按照有关规定继续履行独立董事及其在董 事会专门委员会中的相应职责。 曾艳琳女士在担任公司独立董事期间，勤勉尽责、认真履行职责，充分行使职权，为公司规 ...

Core Insights - The pet economy in China has surpassed 500 billion yuan, maintaining over 20% growth for five consecutive years, driven by social changes, evolving consumer attitudes, and technological advancements [1][4]. Group 1: Observations on the Pet Economy - The pet product consumption is experiencing a refined upgrade, with functional cat food and high-end products growing over 50%, and smart pet products expanding at an annual rate of 35% [4][5]. - The pet service sector has developed a dual-layer consumption structure, with basic services like pet grooming seeing a 180% increase in search volume, and pet insurance adoption rates quadrupling over three years [5]. Group 2: Driving Factors Behind Pet Economy Growth - Social changes, such as aging and declining birth rates, have redefined family structures, with pets providing emotional support for lonely individuals [6]. - There is a shift in consumer perception, with younger generations viewing pets as family members, leading to increased spending on pet-related products and services [7]. - Technological innovations, including IoT and AI, are reshaping the pet industry, enhancing efficiency and standardization [8]. Group 3: Challenges and Concerns in the Industry - The pet market faces issues such as fraudulent practices in live pet trading and a lack of standards in pet food, leading to a 120% increase in consumer complaints in 2024 [10]. - Intense competition has emerged due to significant capital influx, resulting in a "price war" among brands, particularly in the pet supplies sector [11]. - Regulatory frameworks are lagging, with a lack of unified standards in emerging areas like pet insurance and veterinary services [12]. Group 4: Future Trends in the Pet Economy - The industry is expected to see a parallel growth in smart and health-focused products, with health-related spending projected to exceed 40% of total pet expenditures [13]. - Professionalization and standardization of services are anticipated, with leading companies enhancing service quality through brand and chain development [14]. - Cross-industry integration is likely to create new business models, such as pet-themed hotels and training courses, expanding the consumption landscape [15]. Group 5: Benefiting Companies - Guobao Pet is projected to generate 5.244 billion yuan in revenue in 2024, leading the domestic pet business sector, with a 34.82% year-on-year increase in Q1 2025 revenue [16]. - Zhongchong Co. is expected to achieve 4.464 billion yuan in revenue in 2024, ranking second, with a 25.41% year-on-year increase in Q1 2025 revenue [16]. - Tianyuan Pet is anticipated to reach 2.764 billion yuan in revenue in 2024, ranking third among domestic pet companies [16]. - Yuanfei Pet, a leading global pet leash manufacturer, has over 90% of its products exported, with a significant portion of high-margin products [17]. - Ruipu Bio is collaborating with veterinary hospitals to enhance its pet medical services, projecting 690 million yuan in revenue for 2024 [17]. - Yiyi Co. is focusing on disposable pet hygiene products, with a projected revenue of 1.798 billion yuan in 2024 [19].

Core Viewpoint - The animal vaccine sector has shown a significant increase, with a 4.00% rise, ranking third among concept sectors, driven by notable gains in several stocks [1][2]. Group 1: Sector Performance - As of May 20, the animal vaccine concept increased by 4.00%, with 19 stocks rising, including *ST Xianfeng, which hit the daily limit, and others like Kexing Pharmaceutical, Ruipu Biological, and Kanghua Biological, which rose by 15.56%, 8.41%, and 6.70% respectively [1][2]. - The animal vaccine sector was among the top-performing sectors, alongside cultivated diamonds and pet economy, which rose by 4.10% and 4.08% respectively [2]. Group 2: Capital Inflow - The animal vaccine sector saw a net inflow of 67 million yuan, with 13 stocks receiving net inflows, and 6 stocks attracting over 10 million yuan in net inflows [2]. - Jinhe Biological led the net inflow with 36.88 million yuan, followed by Kexing Pharmaceutical, Dabeinong, and Plk, which received net inflows of 15.38 million yuan, 13.79 million yuan, and 13.60 million yuan respectively [2][3]. Group 3: Capital Flow Ratios - Stocks such as *ST Xianfeng, Kexing Pharmaceutical, and KQ Biotech had the highest net inflow ratios, at 14.17%, 6.56%, and 5.52% respectively [3]. - The top stocks in terms of capital inflow included Jinhe Biological with a turnover rate of 18.22% and a daily increase of 4.40%, and Kexing Pharmaceutical with a turnover rate of 3.46% and a daily increase of 15.56% [3][4].